Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories (IDXX) delivers essential diagnostic solutions and practice management tools for veterinary professionals worldwide. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments shaping animal healthcare innovation.
Access official press releases and verified news covering financial results, product launches, regulatory milestones, and strategic partnerships. Our curated collection ensures transparent tracking of IDXX's advancements in in-clinic testing systems, reference laboratory services, and integrated practice software solutions.
Key updates include earnings announcements, diagnostic technology innovations, livestock health initiatives, and global expansion efforts. Bookmark this page for efficient monitoring of developments affecting veterinary diagnostics markets and IDXX's position as a leader in animal health solutions.
Rhea-AI Summary
IDEXX Laboratories, Inc. launches Vello, a pet owner engagement solution, showing an average 19% reduction in no-show rates. Vello streamlines communication between veterinary practices and pet owners, improving practice efficiency and client relationships. Key features include automated appointment reminders, health service reminders, online scheduling, pet owner mobile experience, two-way texting, and pre-appointment instructions. Vello will be available for ezyVet, Neo, and Cornerstone software in the U.S. in March 2024 and Canada in Q2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) achieved 9% revenue growth in the fourth quarter of 2023, driven by 11% reported and 10% organic growth in CAG Diagnostics recurring revenue. The company also delivered fourth quarter EPS of $2.32, an increase of 13% as reported and 17% on a comparable basis. IDEXX provided an initial outlook for 2024 revenue of $3,930 million - $4,040 million, reflecting growth of 7.5% - 10.5% reported and 7% - 10% organic, and estimated 2024 EPS of $10.84 - $11.33, an increase of 8% - 13% as reported and on a comparable basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.53%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) to release 2023 fourth quarter and full year financial results on February 5, 2024. The company will conduct an analyst conference call at 8:30 a.m. ET. Individuals can access a live webcast and transcript of prepared remarks on the IDEXX website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) expands its Fecal Dx antigen testing platform to include Cystoisospora, a common intestinal parasite affecting young dogs and cats. The new testing offers early and accurate detection of various parasites, with the launch planned for March in North America and globally in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announces the global launch of the IDEXX inVue Dx™ Cellular Analyzer, a revolutionary slide-free cellular analyzer for cytology and blood morphology cases in veterinary practices. The platform provides reference-laboratory quality results in 10 minutes, eliminating manual workflow and image analysis steps while generating consistent, clinically actionable results for practitioners and their patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) will participate in two upcoming institutional investor events. Jay Mazelsky, President and CEO, will join the Goldman Sachs Healthcare C-Suite Unscripted Conference in New York, New York on January 4, 2024, and will host an Investor and Analyst Session at VMX in Orlando, Florida on January 15, 2024, to highlight IDEXX’s new point of care analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) announced the upcoming launch of the SNAP® Leish 4Dx® Test, a comprehensive screening test for vector-borne diseases, including canine leishmaniosis. The test uses the trusted SNAP 4Dx Plus testing platform and will be available in Europe and Asia beginning February 2024. The launch provides veterinarians with an end-to-end solution for vector-borne disease testing, including streamlined reference laboratory follow-up testing and compatibility with the SNAP Pro® Analyzer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
-
Rhea-AI Summary
IDEXX Laboratories, Inc. reports third quarter revenue growth of 9% reported and 8% organic. EPS increases by 18% as reported and 16% on a comparable basis. Adjusts 2023 revenue guidance to $3,635 million - $3,650 million. Updates 2023 EPS outlook to $9.74 - $9.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
-
Rhea-AI Summary
IDEXX Laboratories to release 2023 Q3 results on November 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.59%
Tags
Rhea-AI Summary
IDEXX Laboratories, Inc. (NASDAQ: IDXX) reports 10% revenue growth in the second quarter of 2023, driven by CAG Diagnostics recurring revenue growth of 11%. The company achieved record global premium instrument placements and delivered EPS of $2.67, representing 71% growth. Updates 2023 revenue guidance to $3,660 million - $3,715 million and increases 2023 EPS outlook to $9.64 - $9.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
IDEXX Laboratories
Nasdaq:IDXX
IDXX Rankings
IDXX Stock Data
33.35B
80.49M
0.96%
93.21%
3.37%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
United States
WESTBROOK